Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mbiometherapeutics Co. Ltd. has a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is being reviewed by a distinct examiner and is located within 1 distinct art unit. This shows a specific focus for the company's current active prosecution efforts.
The busiest examiner for Mbiometherapeutics Co. Ltd. is DUFFY, PATRICIA ANN, who is handling 1 busiest examiner pending action. For a practitioner, the immediate prosecution strategy is centered on the review by this individual. The presence of only a distinct examiner and art unit means that the company's current patenting activity is concentrated. Success in the pending office action is the primary objective for the portfolio's current status. This centralized structure allows for a focused response to the examiner's findings within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696988 | NOVEL ENTEROCOCCUS FAECIUM LCM001 STRAIN, AND USE THEREOF | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696988 | NOVEL ENTEROCOCCUS FAECIUM LCM001 STRAIN, AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696988 | NOVEL ENTEROCOCCUS FAECIUM LCM001 STRAIN, AND USE THEREOF | DUFFY, PATRICIA ANN | 1645 | §101§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial